Navigation Links
Actavis Announces New Senior Unsecured Term Loan Credit and Guaranty Agreement
Date:8/2/2013

n connection with, and successful close of, Actavis' acquisition of Warner Chilcott (the "Acquisition"); subsequent integration of the Acquisition and the ability to recognize the anticipated synergies and benefits of the Acquisition; the receipt of required regulatory approvals for the Acquisition (including the approval of antitrust authorities necessary to complete the Acquisition); the anticipated size of the markets and continued demand for Actavis' and Warner Chilcott's products; the impact of competitive products and pricing; access to available financing (including financing for the Acquisition or refinancing of Actavis or Warner Chilcott debt) on a timely basis and on reasonable terms; maintaining a position in the Standard & Poor's 500; the risks of fluctuations in foreign currency exchange rates; the risks and uncertainties normally incident to the pharmaceutical industry, including product liability claims and the availability of product liability insurance on reasonable terms; the difficulty of predicting the timing or outcome of pending or future litigation or government investigations; periodic dependence on a small number of products for a material source of net revenue or income; variability of trade buying patterns; changes in generally accepted accounting principles; risks that the carrying values of assets may be negatively impacted by future events and circumstances; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; costs and efforts to defend or enforce intellectual property rights; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with governmental regulations applicable to Actavis' and Warner Chilcott's manufact
'/>"/>
SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Actavis and Warner Chilcott Announce Effectiveness of Registration Statement on Form S-4
2. Actavis Announces 42% Increase to $2.01 in Second Quarter 2013 Non-GAAP Earnings Per Share
3. Actavis and Warner Chilcott Receive FTC Second Request Under Hart-Scott-Rodino
4. Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition
5. U.S. Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis
6. Actavis and Medicines360 Announce Partnership to Advance Womens Access to Affordable IUDs
7. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix
8. Actavis, Inc. to Present at the Goldman Sachs 34th Annual Global Healthcare Conference 2013
9. The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy
10. Actavis NDA for Progestin-Only Patch Accepted for Filing by FDA
11. Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Jan. 4, 2012   Unigene Laboratories, Inc. (OTCBB: ... manufacture and development of peptide-based therapeutics, announced that Ashleigh ... corporate overview at the Biotech Showcase™ 2012 in San ... a.m. PT (2:30 p.m. ET).  Mr. Palmer,s presentation will include ...
... Group, an international generic pharmaceuticals company, today announced ... Food & Drug Administration to market Methylphenidate Hydrochloride ... 40mg.  Actavis has first-to-file exclusivity on the 20mg, ... has commenced.  Methylphenidate Hydrochloride Extended-Release ...
Cached Medicine Technology:Unigene to Present at Biotech Showcase™ 2012 in San Francisco on January 9 2Actavis Launches Generic Equivalent of Ritalin LA® in the US, With 180-Day Exclusivity 2
(Date:4/23/2014)... that proliferation of endogenous neural precursor cells cannot ... axons. From the perspective of neural plasticity, Dr. ... in China observed the effects of functional electrical ... and expression of basic fibroblast growth factor and ... the infarct side. The researchers found that functional ...
(Date:4/22/2014)... been shown to reduce seizures in patients with medication-resistant ... with an innovative electrode placement planning system developed by ... of seizures in nearly half of the implanted Rush ... good news for a large portion of the nearly ... seizures can,t be controlled with medications and who are ...
(Date:4/22/2014)... all lung cancers are small cell lung cancers ... to chemotherapy. However, researchers at Virginia Commonwealth University ... the mechanisms leading to this resistance that may ... primarily by mediating B-cell lymphoma 2 (Bcl-2) family ... Depending on their function, this family of proteins ...
(Date:4/22/2014)... Hopkins scientists have found a way to block abnormal ... of atherosclerosis, the main cause of heart attacks and ... The condition develops when fat builds inside blood vessels ... greatly reducing their ability to feed oxygen-rich blood to ... series of experiments, described April 7 in the journal ...
(Date:4/22/2014)... help rein in massive health care spending, a new ... find ways to incentivize pharmaceutical companies and device makers ... of examining existing medical technologies and their use, a ... what drugs and medical devices get created in the ... care spending with as little loss of health as ...
Breaking Medicine News(10 mins):Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3
... the woman, the less the idea bothered her , , ... comfortable with the idea of childlessness than men, new ... differences in how each gender views the pressures of ... women, parenting and parenthood mean different things," said study ...
... and advocates,to visit Capitol Hill Tuesday, ask Congress to ... WASHINGTON, Oct. 19 With political concerns,growing rapidly on ... of,private equity buyouts of nursing homes, a national caravan ... Monday where they will hold a,demonstration at the Pennsylvania ...
... drugs are unsafe for children under 6, advisers say., , , ... Food and Drug Administration advisory panel on Friday recommended a ... than 6. , Citing a number of studies that showed ... experts also recommended the drugs be tested on children to ...
... Oct. 19 With safety issues making,headlines, ... rugged,regulatory landscape. Organizations are relying on their ... affect production. Proper,staffing of quality roles is ... and a study by pharmaceutical benchmarking leader ...
... 19 The Department of,Labor,s Occupational Safety and ... health instruction that details OSHA policies and procedures,for ... may have,the potential for a dust explosion. ... our efforts on the,fire and explosion hazards that ...
... Ireland, Oct. 19 PulseLearning,(which was founded in 1999 ... on a second-hand computer set up in a child,s ... named fastest growing IT company in,Ireland at the ,2007 ... Awards, now in their eighth year, rank the 50 ...
Cached Medicine News:Health News:Childlessness Bothers Men More Than Women 2Health News:Childlessness Bothers Men More Than Women 3Health News:FDA Panel Recommends Ban on Cold Medicines for Kids 2Health News:FDA Panel Recommends Ban on Cold Medicines for Kids 3Health News:FDA Panel Recommends Ban on Cold Medicines for Kids 4Health News:Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance 2Health News:OSHA Issues New Combustible Dust Instruction 2Health News:PulseLearning (Founded in Child's Bedroom in an Irish Suburban Semi Eight Years Ago and Initially Run on a Second-Hand Computer) Today Named Fastest Growing IT Company in Ireland 2Health News:PulseLearning (Founded in Child's Bedroom in an Irish Suburban Semi Eight Years Ago and Initially Run on a Second-Hand Computer) Today Named Fastest Growing IT Company in Ireland 3Health News:PulseLearning (Founded in Child's Bedroom in an Irish Suburban Semi Eight Years Ago and Initially Run on a Second-Hand Computer) Today Named Fastest Growing IT Company in Ireland 4
Acetate Plate Sealers 100/Box...
... Microseal 'B' seals provide an adhesive-based sealing ... The aggressive adhesive layer ensures secure sample ... and tight sealing during thermal cycling when ... lid. The perforated end-tabs can be removed ...
TD silicone foam compression pad. Use with plates sealed with TDX or OptiTape....
Inquire...
Medicine Products: